Latest / Washington DC News Today | 2 Min News | The Daily News Now!
Ozempic’s Surge and the Cost Crisis | Washington DC News
Ozempic’s skyrocketing popularity—up 643% between 2017 and 2022—isn’t just a diabetes win; it’s a weight-loss phenomenon driving up drug costs and putting pressure on insurers and government programs. While users pay less out of pocket, total expenses are climbing, risking higher premiums for everyone. These GLP-1 drugs, originally for blood sugar control, are now a double-edged sword: powerful for health but financially destabilizing. Experts are racing to find policies that keep them affordable and accessible without breaking the system. Thank you to our sponsor Garrett Waller Performance…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.